KAPA · Kairos Pharma, LTD.
$0.24
+0.00 (+1.22%)
At close · Aug 31
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has experienced recurring losses from operations since inception and incurred a net loss of $3,042 and used cash in operations of $2,048 during the six months ended June 30, 2026. These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$5.62M
Shares
23.70M
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-08-07 | 45,839 | $0.39 | $17,877 |
| 2026-07-31 | 79,515 | $0.30 | $23,855 |
| 2026-07-29 | 4,778 | $0.31 | $1,481 |
| 2026-07-27 | 3,449 | $0.29 | $1,000 |
| 2026-07-24 | 11,372 | $0.30 | $3,412 |
| 2026-07-23 | 70,610 | $0.31 | $21,889 |
| 2026-07-21 | 11,813 | $0.32 | $3,780 |
| 2026-07-20 | 212,848 | $0.31 | $65,983 |
| 2026-07-17 | 608,512 | $0.34 | $206,894 |
| 2026-07-16 | 33,498 | $0.32 | $10,719 |
| 2026-06-29 | 332 | $0.35 | $116 |
| 2026-06-26 | 332 | $0.37 | $123 |
| 2026-06-16 | 845 | $0.44 | $372 |
| 2026-06-10 | 12,851 | $0.43 | $5,526 |
| 2026-06-01 | 335 | $0.51 | $171 |
Showing 1–15 of 15 settlements
Key facts
CIK
1962011
CUSIP
48301N104
13F (30d)
14 filings
14 filers
Visit website
Investor relations